Squamous Cell Carcinoma of Head and Neck Clinical Trials

30 recruiting

Squamous Cell Carcinoma of Head and Neck Trials at a Glance

32 actively recruiting trials for squamous cell carcinoma of head and neck are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 2 with 15 trials, with the heaviest enrollment activity in Lille, Villejuif, and Madrid. Lead sponsors running squamous cell carcinoma of head and neck studies include Janssen Research & Development, LLC, University Health Network, Toronto, and Cancer Research UK.

Browse squamous cell carcinoma of head and neck trials by phase

Treatments under study

About Squamous Cell Carcinoma of Head and Neck Clinical Trials

Looking for clinical trials for Squamous Cell Carcinoma of Head and Neck? There are currently 30 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Squamous Cell Carcinoma of Head and Neck trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Squamous Cell Carcinoma of Head and Neck clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 32 trials

Recruiting
Phase 2

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

Squamous Cell Carcinoma of Head and NeckMetastatic Squamous Cell CarcinomaRecurrent Squamous Cell Carcinoma of the Head and Neck
Washington University School of Medicine46 enrolled1 locationNCT07419464
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled158 locationsNCT04389632
Recruiting
Not Applicable

A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck
The Second Affiliated Hospital of Hainan Medical University32 enrolled1 locationNCT07546383
Recruiting
Phase 1

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Squamous Cell Carcinoma of Head and Neck
Fox Chase Cancer Center22 enrolled2 locationsNCT07455032
Recruiting
Phase 1

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck
Johnson & Johnson Enterprise Innovation Inc.30 enrolled12 locationsNCT07219212
Recruiting
Phase 1Phase 2

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC287 enrolled55 locationsNCT06385080
Recruiting
Phase 3

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC500 enrolled160 locationsNCT07276399
Recruiting
Phase 2

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

Squamous Cell Carcinoma of Head and Neck
University of Arkansas100 enrolled6 locationsNCT05952934
Recruiting
Not Applicable

A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers

Squamous Cell Carcinoma of Head and Neck
University Health Network, Toronto60 enrolled1 locationNCT06085781
Recruiting
Not Applicable

HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers

Squamous Cell Carcinoma of Head and Neck
University Health Network, Toronto40 enrolled1 locationNCT06487403
Recruiting
Phase 2

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Squamous Cell Carcinoma of Head and NeckOral Cavity CancerNasal Cavity Cancer+9 more
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT07063212
Recruiting
Phase 2

Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

Squamous Cell Carcinoma of Head and Neck
Institut Claudius Regaud86 enrolled14 locationsNCT06557889
Recruiting
Phase 1

A Study of MGC026 in Participants With Advanced Solid Tumors

Advanced Solid TumorSquamous Cell Carcinoma of Head and NeckMetastatic Cancer+1 more
MacroGenics250 enrolled12 locationsNCT06242470
Recruiting
Phase 1Phase 2

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

Squamous Cell Carcinoma of Head and NeckSolid TumorColorectal Cancer (CRC)
One-carbon Therapeutics AB43 enrolled4 locationsNCT07151040
Recruiting
Early Phase 1

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

Head and Neck CancerSquamous Cell Carcinoma of Head and NeckSalivary Gland Cancer+1 more
Brigham and Women's Hospital30 enrolled2 locationsNCT05553782
Recruiting
Phase 2

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Squamous Cell Carcinoma of Head and Neck
Barbara Burtness50 enrolled1 locationNCT05317000
Recruiting
Not Applicable

Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck
Centre Henri Becquerel138 enrolled7 locationsNCT04528420
Recruiting

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and NeckCutaneous Squamous Cell Carcinoma (CSCC)Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)+1 more
University of California, San Francisco250 enrolled1 locationNCT06606028
Recruiting
Phase 1Phase 2

A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck
Sichuan Baili Pharmaceutical Co., Ltd.130 enrolled1 locationNCT05668858
Recruiting
Phase 3

2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck
Sun Yat-sen University422 enrolled5 locationsNCT06492460